Halo Biosciences
Editing the extracellular matrix to transform disease
Halo Biosciences
Editing the extracellular matrix to transform disease
Our Mission
Halo is a biotechnology company focused on creating first-in-class, disease-modifying therapies using innovative approaches to edit the extracellular matrix (ECM)
Our Science
The ECM in Disease
We are building a differentiated pipeline based on novel insights into how hyaluronan (HA) dysregulation drives disease
Alterations to HA and to the ECM have strong associations with a variety of conditions characterized by inflammation and fibrosis, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis
Our Pipeline
A novel approach to ECM editing
Our pipeline is focused on delivering first-in-class and best-in-class hyaluronan remodeling agents, acting on novel targets with a differentiated mechanism of action
Our lead indications are in diseases with high unmet need characterized by inflammation, fibrosis, and immunologic imbalances